WARNING TO DELAY IN DIAGNOSING MICROSCOPIC COLITIS IN OLDER ADULTS. A SERIES OF CASES

• Published in: Arquivos de gastroenterologia 2024, Vol.61, p.e23114
• Main Authors: Kotze, Lorete Maria da Silva, Kotze, Luiz Roberto, Souza, Raquel Canzi Almada de, Kotze, Paulo Gustavo, Nisihara, Renato
• Format: Article
• Language: English
• Subjects: Aged; Budesonide - therapeutic use; chronic diarrhea; Colitis, Microscopic - diagnosis; Colitis, Microscopic - drug therapy; diagnosis, treatment; Diarrhea - drug therapy; Diarrhea - etiology; Female; GASTROENTEROLOGY & HEPATOLOGY; Humans; Inflammatory Bowel Diseases; Male; Microscopic colitis; Pathologic Complete Response; Quality of Life
• ISSN: 0004-2803; 1678-4219; 1678-4219
• DOI: 10.1590/S0004-2803.24612023-114

Microscopic colitis (MC) is a chronic inflammatory bowel disease causing non-bloody diarrhea, and several cases are undiagnosed as a hidden cause of chronic diarrhea. We aimed to report the symptoms, delay diagnosis and the treatment of MC in a case series. All patients were treated at a Gastroenterology reference office from May 2022 to June 2023. Personal history including preexisting disorders, use of medications and smoking habits were collected. The delay between the onset of symptoms and the correct diagnosis was informed. All patients consented to use budesonide MMX (Corament®) off label. During the study period, six Caucasoid patients were diagnosed with MC, five females and one male, between the ages of 65 and 74. All patients had comorbities and were taking multiple prescription drugs. Laboratory findings showed negative serology for celiac disease for all patients, normal levels of albumin and vitamin B12. The delay between the symptoms and the MC diagnosis varied from 2 months to 6 years. All patients had a previous diagnosis of irritable bowel syndrome. All patients were in complete clinical remission during the treatment and referred no side effects of the drug. Older females using high-risk medications are suggestive of MC. Preventing delay in the diagnosis of MC is crucial to improvement in patients´ quality of life. Budesonide MMX appears to be effective, safe and well-tolerated.